Menactra Vaccine

Share This:

Ready to Help Whenever You Need Us

We know who to talk to, where to find answers, and what steps you need to take. Let us put our 30 years of experience to work for you.

Menactra Meningococcal Vaccine

On October 20, 2005, the Food and Drug Administration (FDA), along with the Centers for Disease Control and Prevention (CDC), updated a previous alert which announced that they are investigating the possibility of a link between Menactra Meningococcal Vaccine and Guillain Barre Syndrome (GBS). The investigation has found 15 confirmed cases of GBS in patients who had received the Menactra Meningococcal Vaccine manufactured by Sanofi Pasteur.

Guillain Barre Syndrome (GBS)

  • Guillain Barre Syndrome (GBS) is a neurological disorder that may require hospitalization.
  • Symptoms typically include increased weakening in the legs and arms. In severe cases, paralysis may occur.
  • Although most patients with GBS recover after a few weeks, some people suffer with these symptoms for months or years.
  • In the most serious cases of paralysis, a patient may die from the disease.

Menactra Meningococcal Vaccine

  • The Menactra vaccine was approved in January 2005 to protect against bacterial meningitis.
  • The vaccine is typically given to adolescents before high-school entry. It is also recommended for first-year college students living in dormitories.
  • The FDA reports that more than 2.5 million doses of Menactra Meningococcal Vaccine have been administered in the U.S.

If you or your loved one has suffered a Menactra vaccine injury, contact us today. Submit the form to the right and we’ll let you know if you have a case and if we can represent you.